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A B S T R A C T
Purpose: To evaluate the safety of eslicarbazepine acetate (ESL) in new onset elderly poststroke seizure
patients, especially with respect to hyponatremia.
Method: In a two year, single center open labeled observational study of ESL in patients with imaging
proven stroke with new onset post stroke seizure were included. ESL was titrated between 400 mg and
1200 mg once daily during 1 month observation period. The titrated dose of ESL was continued during
96-week maintenance period. The patients were followed up for seizure control and side effects,
including serum sodium on ﬁrst examination, at the end of 1 month and then at three monthly intervals
for 24 months (total eight visits).
Result: Hyponatremia developed in four out of 32 (12.5%) patients; it was symptomatic in three and
asymptomatic in one patient. No statistically signiﬁcant difference between mean sodium levels at
different time period, compared to baseline was found.
Conclusion: High incidence of hyponatremia in ESL treated post stroke patients, was found,
hyponatremia symptoms since can be subtle and delayed, so monitoring of serum sodium in the
patients on ESL treatment is recommended especially in elderly.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Esclicarbazepine acetate (ESL) is a third generation antiepileptic
drug (AED) with sodium channel blocking property with the
advantage of once daily dosing. In three phase III randomized
controlled trials, ESL has been found to be effective and safe in
partial and secondary generalized epilepsy [1]. ESL belongs to the
dibenzazepine family; the other members of this group are
Carbamazepine (CBZ), and Oxcarbazepine (OXC). In neurologic
patients, hyponatremia is not only the most common electrolyte
imbalance. It is more common in neurologic patients than the
patient with other diseases [2,3]. For both CBZ and OXC
hyponatremia is one of the most common causes of treatment
withdrawal limiting their use in neurological patients [4]. Since
hyponatremia has been observed rarely (0.6–1.3%) in patients
treated with ESL during the pre-marketing clinical trials [5], in this
prospective study; we examine the safety of ESL in poststroke
seizure patients especially with respect to hyponatremia.* Corresponding author at: Department of Neurology, Sanjay Gandhi Post
Graduate Institute of Medical Sciences, Raebareily Road, Lucknow 226014, India.
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2.1. Study design
In a two year, single center open labeled observational study of
ESL in patients with CT or MRI proven stroke with new onset post
stroke seizure were included. The criteria of the Commission on
Classiﬁcation and Terminology of the International League against
epilepsy were followed to differentiate between focal and focal
with generalized epilepsy [6]. The type of stroke was divided into
hemorrhagic or ischemic, and the etiologic subtypes of ischemic
stroke were classiﬁed according to the Trial of ORG 10172 in Acute
Stroke Treatment (TOAST) criteria [7].
ESL dose was titrated between 400 mg and 1200 mg once daily
during 1 month observation period. The titrated dose of ESL was
continued during the subsequent 96-weeks maintenance period.
The patients were followed up for seizure control and side effects,
including serum sodium on ﬁrst examination, at the end of the
observation period (1 month) and then at three monthly intervals
for 24 months (Total eight visits). Patients having seizures on a
daily ESL dose of 1200 mg were considered nonresponders and
were switched to another AED, concomitant AEDs were not
allowed. The clinician was free to decrease the dose of ESL or
withdraw it if the patient had side effects.served.
Table 1
Baseline clinical characteristics of post stroke seizure patients.
Clinical characteristics Stroke n (%)/(M  SD)
Age (yrs), mean (SD) 51.88  15.17
NIHSS mean (range, SD) 8.90  3.94
Gender type, n (%)
Male 24 (75.0%)
Female 8 (25.0%)
Addiction, n (%)
Smoking 2 (6.3%)
Alcoholic 2 (6.3%)
Tobacco chewer 4 (12.5%)
Tobacco and alcohol both 3 (9.4%)
Comorbidities, n (%)
Hypertension 17 (53.1%)
Diabetes mellitus 9 (28.1%)
Heart disease 5 (15.6%)
Baseline dementia 2 (6.3%)
Stroke type, n (%)
Infarct 23 (71.9%)
Hemorrhage 9 (28.1%)
Etiology of ischemic stroke-TOAST criteria,a n (%)
Large vessel atherosclerosis 12 (35.5%)
Cardioembolism 5 (16.1)
Small vessel occlusion 1 (3.2%)
Stroke of other determined etiology 4 (12.9%)
Seizure seminology, n (%)
Focal 3 (9.4%)
Focal with generalization 22 (68.8%)
GTCS 7 (21.9%)
Seizure temporal proﬁle, n (%)
Early 14 (43.8%)
Late 18 (56.2%)
a Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria for etiologic
subtypes of ischemic stroke [5].
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The study was approved by the Institutional Ethics Committee
(PGI/BE/359/2014). Data were expressed in mean  standard
deviation (SD). The continuous variables were analyzed by Students
‘t’ test and categorical data by chi square test. The difference between
the two means was considered statistically signiﬁcant if two tailed p
value was < 0.05. The statistical analysis was done using SPSS version
16 software.
2.2. Inclusion criteria
1. Imaging (CT/MRI) proven stroke with the occurrence of seizures
within 7 days (early) or after 7 days (late) post stroke seizure
2. Age 18 years
3. Having sodium level (Na+) evaluated at baseline, 1 month, and
then at 3 months. Normal serum sodium was deﬁned as Na+
135–145 mEq/L, hyponatremia as Na+  134 mEq/L, and severe
hyponatremia as Na+  128 mEq/L.
2.3. Exclusion criteria
Patients, who had poststroke seizures only in speciﬁc circum-
stances, such as electrolyte imbalance and other metabolic
conditions, were not included in this study. The patients with
heart, liver or kidney failure were also excluded as these can affect
serum sodium level. Other exclusion criteria were: pregnancy,
history of status epilepticus, neoplastic disease, known allergy or
contraindications to the use of ESL and life expectancy 1 year.
Before ascribing hyponatremia to ESL, other causes of hypona-
tremia such as diuretic or poor salt intake were excluded, if
hyponatremia persisted after withdrawing any other alleged drug
and corrected after withdrawing ESL, it was attributed to ESL.
2.4. Management
The patients with hyponatremia were treated by withdrawing
the offending drugs if any and sodium supplementation orally or
intravenously/ﬂuid restriction depending on the clinical and
biochemical ﬁndings. Other treatments for stroke and co
morbidities were prescribed as per the treating physician’s
decision.
3. Result
Thirty-three patients were enrolled in the study between July
and October 2012. Thirty-two of them were followed for a period of
2 years (96 weeks); one patient was lost from follow up. Eighteen
patients (58.3%) received ESL 800 mg, 13 (40.6%) 600 mg and 1
(3.1%) 1200 mg daily. There baseline clinical characteristics were
given in Table 1.
The side effects of ESL were fatigue in four (12.5%) patients,
somnolence in two (6.3%), rash in one (3.1%), ﬂu like symptoms in
one (3.1%), ataxia in one (3.1%), and hyponatremia in four (12.5%)
patients. Although hyponatremia developed in 4 (12.5%) patients,
no statistically signiﬁcant difference between mean sodium levels
at different time period compared to baseline was found (Fig. 1)
and all four patients who developed hyponatremia were in ESL
800 mg group. Fig. 2 shows the levels of serum sodium during 2
years followup amongst patients with or without hyponatremia,
although there were ﬂuctuation but usually serum sodium remains
1–2 mEq/L below the baseline levels. In three patients hypona-
tremia was severe requiring drug withdrawal. Our fourth patient
presented with asymptomatic hyponatremia detected on followup
visit, he was advised to increase salt intake with monitoring of ﬂuid
intake and output, he responded to it and was eunatremic on nextvisit while maintaining the same dose of ESL, he is asymptomatic
and his serum sodium is normal since then. The case report of
patient no 1 is described, clinical details of other patients with
hyponatremia are presented in Table 2.
3.1. Case report #1
A 40-year male with hypertensive caudate hemorrhage
developed two episodes of focal seizure with generalization on
1st and 2nd day of stroke; the seizure lasted 3–5 min. He was
prescribed ESL 800 mg, Amlodipine 5 mg, Atenolol 25 mg and
Hydrochlothiazide 12.5 mg daily. On seventh month followup he
was found to be lethargic, complained of weakness and nausea. On
examination he was confused, afebrile with normal skin turgor, his
serum sodium was 113 mEq/L, potassium 3.1 mEq/L, albumin was
3.3 g/dl, uric acid 3.0 mg/dl, thyroid stimulating hormone
1.27 miu/L, his serum osmolality was 272 mOsm/kg, urine
osmolality 253 mOsm/kg, and urinary sodium 43 mEq/L, sugges-
tive of syndrome of inappropriate secretion of antidiuretic
hormone (SIADH), since his seizure were well controlled with
ESL till 7 months, hydrochlorthiazide induced hyponatremia was
considered and the diuretic was withdrawn. The patient was
prescribed salt supplementation along with ﬂuid restriction, on
3rd day of illness, his serum sodium was still found to be low
(116 mEq/L), ESL was then substituted with Levetiracetam (LEV).
Within 2 days his sodium improved to 128 mEq/L, he became
eunatremic on the 10th day of admission, discharged on LEV and
since then he is asymptomatic.
4. Discussion
Our study reveals that four out of 32 (12.5%) patients with post
stroke seizures on ESL developed hyponatremia (symptomatic in 3
and asymptomatic in 1), which occurred after a mean duration of
Fig. 2. Fluctuation of mean serum sodium at different time periods to baseline
among patient with and without hyponatremia. Patient number (n = 4/32). Serum
sodium level gradually declines during the ﬁrst month of treatment and remain
approximately 1–2 mEq/L below baseline levels.
Fig. 1. Comparison of serum sodium at different time periods to baseline values are
in mean  SD, *p value with respect to baseline, patient number (n = 32).
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due to ESL because it had a temporal relationship to introduction of
ESL; there was no other offending cause of hyponatremia such asTable 2
Summarizing the clinical and laboratory ﬁndings in the patient’s with ESL associated h
Parameter Patient 1 Patient 2 
Age (years)/sex 40/male 55/male 
Stroke type Hypertensive caudate
hemorrhage
Hypertension, diabetes
mellitus and multi infa
state with poststroke s
Time of Na+deﬁcit 7th month 4th month 
Lowest Na+ level 113 mEq/L 126 mEq/L 
Symptoms of
hyponatremia
Nausea, lethargy, weakness Weakness and asthenia
Volume status
Serum osmolality
Urine output
Urine osmolality
Euvolemic
272 mOsm/kg
Normal to low
253 mOsm/kg
Euvolemic
268 mOsm/kg
Normal to low
167 mOsm/kg
Reversal of
hyponatremia
On 10th day with ﬂuid
restriction and salt
supplementation, ESL
withdrawn
On 3rd day with ﬂuid r
and salt supplementati
withdrawn
Other offending factors Diuretica None 
a Thinking of hydrochlorthiazide induced hyponatremia, ﬁrst diuretic was withdrawn a
still low, then ESL was withdrawn and substituted with Leveteracetam. Within 2 daysheart failure, or endocrine abnormality. Only one patient received
thiazide diuretic. In this patient, hyponatremia persisted even after
withdrawing the diuretic and responded to ESL withdrawal as in
other patients.
In our study incidence of hyponatremia is higher than that
reported in the literature where it has been reported in only 0.6% to
1.3% in the premarketing clinical trials [1]. In three controlled
epilepsy studies, 1/196 patients (0.5%) treated with 400 mg, 4/415
patients (1.0%) treated with 800 mg, and 6/410 patients (1.5%)
treated with 1200 mg of ESL had one or more serum sodium values
less than 125 mEq/L during treatment whereas none in placebo
group [5]. In contrast hyponatremia is the most frequently
reported adverse drug reactions in the post-marketing database
for Aptoim [8] (ESL brand approved by the US FDA). In this database
there were 140 cases of hyponatremia, in half of them hypona-
tremia occurred within the recommended range of 400–1200 mg
of ESL and sodium level as low as 103 mEq/L had been reported [8].
In our study all four patients who developed hyponatremia were in
ESL 800 mg group, and lowest sodium level recorded was
113 mEq/L. As hyponatremia develops across all dose ranges of
ESL, thus it appears that ESL induced hyponatremia is probably not
dose dependent.
Data regarding time interval between initiation of ESL to
development of hyponatremia is scarce, In three controlled
epilepsy trials and post marketing studies, hyponatremia generally
appeared within the ﬁrst 8 weeks of treatment (as early as after 3
days) and, and in some cases lead to ESL withdrawal [1,5,8], in
comparison followup studies on OXC shows that oxcarbazepine-
associated hyponatremia develops slowly over several weeks and
months [9]. Evidence indicate that small mean sodium value
decreases usually occurs in all OXC treated patients with epilepsy
This small mean decrease occurs mostly within the ﬁrst 2 months
after treatment initiation and does not change over time, unless
sodium depleting drugs, are added [10], since ESL matches OXC in
many aspects [1] so it is also likely to cause delayed hyponatremia
and majority of the patients are supposed to be asymptomatic.
Absence of long term followup again may be the reason behind the
low incidence of hyponatremia attributed to ESL in previous
studies. In our study one patient was asymptomatic, in which
hyponatremia was detected in 3rd month. Amongst the symptom-
atic patients with ESL related hyponatremia, one was having
diuretic coadministration, presented to us in the 7th month. We
could not ﬁnd any precipitating factor in other two symptomatic
patients with delayed presentation.yponatremia.
Patient 3 Patient 4
76/female 60/male
rct
eizure
Right middle
cerebral artery territory
and anterior cerebral
territory (partial) infraction
Thalamic hemorrhage,
hypertension
15th month 3rd month
124 mEq/L 129 mEq/L
 Decrease oral intake
and drowsiness
Asymptomatic
Euvolemic
266 mOsm/kg
Normal to low
202 mOsm/kg
Euvolemic
268 mOsm/kg
Normal
210 mOsm/kg
estriction
on, ESL
On 5th day with ﬂuid
restriction and salt
supplementation, ESL
withdrawn
Was eunatremic at next
visit with salt supplementation
None None
nd he was kept on salt supplementation along with ﬂuid restriction, but sodium was
 his sodium improved to 128 mEq/L.
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reduction or discontinuation and alternative anti-epileptic medi-
cation should be considered [8,11], along with salt supplementa-
tion and ﬂuid restriction depending upon intake-output charting,
all three symptomatic patients in our study responded to ESL
withdrawn along with these measures. Management of patients
with asymptomatic hyponatremia detected during routine visit is
not well established. They should be put on close followup, warned
about possible symptoms of hyponatremia (e.g., nausea, malaise,
headache, lethargy, confusion, obtundation, or increase in seizure
frequency or severity), along with regular sodium level monitoring
particularly if the patient has had a previous history of
hyponatremia, has other comorbidities, or is receiving other
medications concurrently known to decrease serum sodium level
(e.g., diuretics, drugs associated with SIADH) [8,11].
The high incidence of hyponatremia in our study may be due to
old age of the patients (51.88  15.17 years) with co morbidities
such as diabetes and hypertension. Age is an important risk factor for
hyponatremia in ESL treated patients. In an uncontrolled study, in 72
elderly (aged 65 years) patients on ESL, the incidence of
hyponatremia was 8.3% [12]. There is probably a subset of patients
with epilepsy who are inherently susceptible to ESL induced
hyponatremia [4]. Bucher et al. [13], in their study found a bimodal
distribution of Na+ in persons exposed to risk factors for SIADH, they
suggested that SIADH may only affect a genetically distinct
vulnerable subpopulation. Occurrence of ESL induced hyponatremia
across all dose ranges also support this hypothesis. Our study group
was a selected cohort of post stroke seizure patients, stroke in itself
may cause hyponatremia due to cerebral salt wasting or SIADH, these
abnormalities however would appear earlier rather than after several
months.
ESL differs from OXC as it is metabolized almost exclusively to
the (S) enantiomer (designated as S-licarbazepine) with less than
5% chiral conversion to the (R)-enantiomer [1]. Possible mecha-
nism of ESL induced hyponatremia can be understood by the
mechanism of hyponatremia in OXC. Sachdeo et al. found that OXC
intake results in signiﬁcant reductions in serum osmolality and
serum sodium concentration after a water–load test, This
hypotonic hyponatremia, which is not associated with a signiﬁcant
change in serum arginine vasopressin (AVP), is the result of both a
relative inability to dilute the urine and a reduction in the
percentage of water excreted after the water–load test [14]. He
suggested that OXC induced hyponatremia is not attributable to
the SIADH. Possible mechanisms include a direct effect of OXC on
the renal collecting tubules or an enhancement of their respon-
siveness to circulating AVP [14]. Irrespective of the possible
mechanism there occurs a euvolemic hyponatremia that responds
to ﬂuid restriction, salt supplementation with or without ESL
withdrawal.
Ours is a select group of elderly stroke patients with
comorbidities and is not representative of true population. We
although excluded the patients with other potential causes of
hyponatremia like heart failure, cirrhosis of liver and renal failure
but there is possibility of missing the patients with subclinical
abnormalities. With sodium level estimation at baseline, 1 month
and then at 3 months interval and in symptomatic patient at onset
of symptoms, there is a chance of missing the patient with short
lasting asymptomatic hyponatremia developing in between these
visits. Our study has a small sample size; a larger study is needed to
estimate the exact incidence of hyponatremia in ESL. We have not
measured the ESL serum concentration so we cannot deﬁnitely
state that ESL induced hyponatremia is dose independent.
The difﬁculty of diagnosis of ESL related hyponatremia is due to
asymptomatic hyponatremia as one of our patients had no
symptoms. In CBZ/OXC related hyponatremia also usually the
patients are asymptomatic [4]. Neurological abnormalities such asstupor, convulsion and coma occurs when serum sodium falls
below 110 mEq/L [15]. High frequency of hyponatremia in our
study justiﬁes the need of regular sodium monitoring in elderly
patients on ESL therapy especially if they have comorbidities.
5. Conclusion
In conclusion we found a high incidence of hyponatremia in ESL
treated post stroke patients, since symptoms of hyponatremia can
be subtle and delayed, so we recommend close follow up and
regular sodium level monitoring of patients on maintenance
treatment of ESL, especially in elderly patients.
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